MAIA MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. (MAIA) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.5% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MAIA Biotechnology, Inc.
MAIA Biotechnology Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. MAIA Biotechnology Inc. is based in CHICAGO.
Sector
Healthcare
Industry
Biotechnology